SOPHiA GENETICS SA Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%

Reuters

08/05

<a href="https://laohu8.com/S/SOPH">SOPHiA GENETICS SA</a> Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%

SOPHiA GENETICS SA has released its unaudited interim financial results for the first half of 2025. The company reported a revenue increase to $36.1 million for the six months ended June 30, 2025, compared to $31.6 million in the same period in 2024, marking a significant rise. However, the company recorded a loss before tax of $38.5 million for the first half of 2025, compared to a loss of $28.4 million in the corresponding period of the previous year. A notable increase in share-based compensation, which rose to $8.2 million from $7.8 million in 2024, contributed to the overall financial results. The company has not provided any specific outlook or guidance for future periods in the released interim statements. SOPHiA GENETICS continues to operate in a single segment, with its revenues being assessed across Europe, the Middle East, and Africa (EMEA); North America (NORAM); Latin America (LATAM); and Asia-Pacific (APAC).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840706-25-000026), on August 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557360408"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557360408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557360408?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557360408","market":"us","top_or_hot":-1,"title":"SOPHiA GENETICS SA Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SOPH\">SOPHiA GENETICS SA</a> Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SOPHiA GENETICS SA has released its unaudited interim financial results for the first half of 2025. The company reported a revenue increase to $36.1 million for the six months ended June 30, 2025, compared to $31.6 million in the same period in 2024, marking a significant rise. However, the company recorded a loss before tax of $38.5 million for the first half of 2025, compared to a loss of $28.4 million in the corresponding period of the previous year. A notable increase in share-based compensation, which rose to $8.2 million from $7.8 million in 2024, contributed to the overall financial results. The company has not provided any specific outlook or guidance for future periods in the released interim statements. SOPHiA GENETICS continues to operate in a single segment, with its revenues being assessed across Europe, the Middle East, and Africa (EMEA); North America (NORAM); Latin America (LATAM); and Asia-Pacific (APAC).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840706-25-000026), on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SOPHiA GENETICS SA Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSOPHiA GENETICS SA Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-05 18:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SOPH\">SOPHiA GENETICS SA</a> Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SOPHiA GENETICS SA has released its unaudited interim financial results for the first half of 2025. The company reported a revenue increase to $36.1 million for the six months ended June 30, 2025, compared to $31.6 million in the same period in 2024, marking a significant rise. However, the company recorded a loss before tax of $38.5 million for the first half of 2025, compared to a loss of $28.4 million in the corresponding period of the previous year. A notable increase in share-based compensation, which rose to $8.2 million from $7.8 million in 2024, contributed to the overall financial results. The company has not provided any specific outlook or guidance for future periods in the released interim statements. SOPHiA GENETICS continues to operate in a single segment, with its revenues being assessed across Europe, the Middle East, and Africa (EMEA); North America (NORAM); Latin America (LATAM); and Asia-Pacific (APAC).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840706-25-000026), on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOPH","symbol_name":"SOPHiA GENETICS SA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL55BqLT:1","article_id":"2557360408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557360408","pubTimestamp":1754390180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SOPHiA GENETICS SA has released its unaudited interim financial results for the first half of 2025. The company reported a revenue increase to $36.1 million for the six months ended June 30, 2025, compared to $31.6 million in the same period in 2024, marking a significant rise. However, the company recorded a loss before tax of $38.5 million for the first half of 2025, compared to a loss of $28.4 million in the corresponding period of the previous year. A notable increase in share-based compensation, which rose to $8.2 million from $7.8 million in 2024, contributed to the overall financial results. The company has not provided any specific outlook or guidance for future periods in the released interim statements. SOPHiA GENETICS continues to operate in a single segment, with its revenues being assessed across Europe, the Middle East, and Africa ; North America ; Latin America ; and Asia-Pacific .","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SOPH":"SOPHiA GENETICS SA"},"translate_title":"SOPHiA GENETICS SA报告六个月收入增长15.9%，净亏损扩大35.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOPH":0.9},"content_text":"SOPHiA GENETICS SA Reports 15.9% Increase in Six-Month Revenue, Net Loss Widens by 35.5%\n    \n\n        SOPHiA GENETICS SA has released its unaudited interim financial results for the first half of 2025. The company reported a revenue increase to $36.1 million for the six months ended June 30, 2025, compared to $31.6 million in the same period in 2024, marking a significant rise. However, the company recorded a loss before tax of $38.5 million for the first half of 2025, compared to a loss of $28.4 million in the corresponding period of the previous year. A notable increase in share-based compensation, which rose to $8.2 million from $7.8 million in 2024, contributed to the overall financial results. The company has not provided any specific outlook or guidance for future periods in the released interim statements. SOPHiA GENETICS continues to operate in a single segment, with its revenues being assessed across Europe, the Middle East, and Africa (EMEA); North America (NORAM); Latin America (LATAM); and Asia-Pacific (APAC).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840706-25-000026), on August 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}